Key Figures (in EUR thousand)

• Revenues: 1,831 in 9M 2008; (9M 2007: 1,809)
• EBIT: -8,536 in 9M 2008; improved by 16% (9M 2007: -10,179)
• Net loss: -8,147 in 9M 2008; reduced by 17% (9M 2007: -9,838)
• Liquid assets: 15,162 at end of September 2008 (Dec 31, 2007: 10,016)

Highlights of Q3 2008

• Progressed PRESEPT Clinical Study
• Executed according to plan in colorectal cancer blood test commercialization· Key patent granted in Europe
• Completed clinical study for prognostic prostate cancer tissue test with excellent results
• Initiated additional clinical study in lung cancer program
• Strengthened management with industry experts in product development and marketing

Berlin, Germany and Seattle, WA, USA

• Successfully qualified 17 PRESEPT clinical sites; 12 sites initiated
• Enrollment nearly 500 subjects in first three months
• Expanded clinical site network to include first site in Germany
• Launched PRESEPT Study website found at www.presept.net
• Added Prof. Dr. Thomas Rösch to the Clinical Study Steering Committee
• Appointed Dr. Timothy R. Church responsible for study results analysis
• Clinical Study Steering Committee recommends strengthening design by dropping interim analysis

Berlin, Germany and Seattle, WA, USA

• Clinical study with patient cohorts from multiple clinical centers completed
• All study endpoints met 
• PITX2 biomarker classifies patients into groups at high and low risk for relapse

Press Release Berlin and Seattle, WA, USA

• Clinical study of over 500 patient samples well on track for completion in Q4 2008
• Interim analysis representing approximately half of the cases demonstrates statistical significance for primary endpoint of prostate cancer prognosis (probability of recurrence)
• PITX2 biomarker classifies patients into groups at high and low risk for relapse following surgery

Berlin, Germany and Seattle, WA, USA

Key Figures (in EUR thousand)

• Revenues: 1,511 in H1 2008; increased by 13% (H1 2007: 1,343)
• EBIT: -5,888 in H1 2008; improved by 15% (H1 2007: -6,949)
• Net loss: -5,632 in H1 2008; reduced by 16% (H1 2007: -6,699)
• Liquid assets: 17,753 at end of H1 2008 (Year end 2007: 10,016)

Highlights of the Successful First Half of 2008 and Year to Date

• Solid revenue growth, improved EBIT and reduced net loss
• Secured future funding via capital increase, “Epi 2010” initiative to evolve the commercial organization
• Signed Septin 9 licensing deal with Quest Diagnostics
• Confirmed new Septin 9 assay for colorectal cancer blood test in clinical studies
• Received notice of allowance for key Septin 9 patent in Europe
• Initiated PRESEPT study in colorectal cancer program
• Successfully completed two clinical studies in lung cancer program
• Generated additional data on tissue and urine samples in prostate cancer program
• Signed technology licensing deals with OncoMethylome Sciences and DxS
• Management evolution continues with hire of new Sr. VP Product Development

Press Release, Berlin, Germany and Seattle, WA, USA,

Multi-center study in U.S. and Germany enrolling up to 7,500 individuals aims at demonstrating the benefits of colorectal cancer population screening with Epigenomics’ Septin 9 blood test

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

Biomarker panel opens up additional application areas based on excellent bronchial lavage test results

Press Release, Berlin, Germany, and Seattle, WA, U.S.A.

Key Figures 

• Revenue: EUR 0.9 million in Q1 2008, up by 12% (Q1 2007: EUR 0.8 million) 
• EBIT: EUR -3.0 million in Q1 2008, improved by 13% (Q1 2007: EUR -3.4 million) 
• Net loss: EUR -2.9 million in Q1 2008, improved by 12% (Q1 2007: EUR -3.3 million) 
• Liquid assets: Strengthened at EUR 21.2 million as of 31/03/2008 (31/12/2007: EUR 10.0 million)

Highlights of the First Quarter 2008

• All key financials within expectations: Revenue, EBIT and net loss improved 
• Successful capital increase secures funding and provides financial framework for further strategy execution 
• Launch of “Epi 2010”, a management initiative to extend cash resources: Focus entirely on cancer screening products and further streamlining of organization 
• Strategic partnership signed with Quest Diagnostics
• Licensed key technologies to OncoMethylomeSciences 
• Launch of first RUO products with partner TIB MOLBIOL 
• Optimized assay for colorectal cancer screening test clinically validated and novel biomarkers in prostate cancer program identified 
• Final preparation of major colorectal cancer screening study PRESEPT to start in Q2 2008

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

Performance of Septin 9 assay optimized for clinical routine application confirmed as equivalent to earlier research assay – Blood test successfully run in more than 500 additional patient samples

Press release, Berlin, Germany, and Seattle, WA, U.S.A.

Products for high-quality DNA methylation analysis to support early adoption and drive market acceptance of Epigenomics’ proprietary cancer biomarkers

Press release, Berlin, Germany, and Seattle, WA, U.S.A.

Successful execution on corporate strategy – Financial and strategic framework set for the future

Financials in line with latest expectations:

• Full year revenue EUR 2.6 million
• Operational costs reduced by EUR 3.8 million, EBIT improved by 14% to EUR (13.5 million)
• Successfully completed PIPE transaction, liquidity position at EUR 10 million as of December 31 2007
• Capital increase in early 2008 secures funding and provides financial framework for further strategy execution
• “Epi 2010”: management initiative to extend cash resources

Management delivered on corporate strategy:

• Licensed colorectal cancer test to Abbott Molecular as the first non-exclusive IVD-partner
• Licensed colorectal cancer Septin 9 biomarker to Quest Diagnostics in early 2008
• Set the stage for major clinical colorectal cancer screening cohort study PRESEPT to start in Q2 2008
• Further progressed prostate and lung cancer development programs
• Further secured protection of diagnostic body fluid and tissue workflows with key technology patents granted
• Expanded licensing agreement with Qiagen to include IVD sample preparation solutions

Press Release, Berlin, Germany and Seattle, WA, U.S.A.

• Standard-setting in DNA methylation on Epigenomics technology continues 
• Enhanced flexibility for commercial test development for DxS and Epigenomics
  

Press Release, Berlin, Germany, and Manchester, UK,